Fiche centre
Centrum Medyczne Pratia Katowice
Katowice — Poland
Essais liés4clinical trials
VilleKatowicelocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06047444
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |
| Orelabrutinib | SEP | Phase 3 | NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047457 | E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047444 | C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |